Bevacizumab is an angiogenesis inhibiting monoclonal antibody and is commonly used to treat certain metastatic cancers.
|Mechanism of Action||Bevacizumab can inhibit tumor growth in a few different ways including inhibiting new blood vessel growth, altering vascular function and blood flow in tumor, and regression of newly formed tumor vasculature.|
|Spectrum||Bevacizumab is effective at treating metastatic colon cancer, lung cancers, renal cancers, ovarian cancers, and breast cancer.|
|References||Ellis, Lee M. "Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer." Seminars in Oncology 33 (2006)|